NICE Clears Enhertu After the UK-US Pricing Deal

NICE has cleared Enhertu for about 1,000 people a year in England with HER2-low advanced breast cancer. Doctors have been able to offer trastuzumab deruxtecan, made by Daiichi Sankyo and AstraZeneca, since 17 September 2026, after a commercial deal and a rise in the watchdog’s value-for-money bar.

The science behind that yes is four years old. What moved is the price the NHS is now allowed to pay, under a UK-US medicines arrangement signed to keep tariffs off British drug exports.

NICE Recommends Enhertu for About 1,000 People a Year

The National Institute for Health and Care Excellence recommended it for routine NHS use in adults whose HER2-low advanced or metastatic disease has grown after treatment. For this group, Enhertu had been the only breast cancer drug NICE could not recommend since 2018, a stretch in which 25 other breast cancer treatments won a yes.

Helen Knight, director of medicines evaluation at NICE, tied the reversal to money and method, not a new trial.

I’m pleased that a commercial solution, alongside recent changes to NICE’s cost-effectiveness thresholds and the use of new methods for assessing quality-of-life, has meant this treatment can now be provided on the NHS. However, we know this decision comes too late for many families, and our thoughts are with them today.

Helen Knight, director of medicines evaluation, NICE

Dr Anne Rigg, consultant medical oncologist and NHS England’s national specialty adviser for chemotherapy, said women can access the drug from 17 September 2026. The final draft can still be appealed until 5pm on 7 October 2026. Health Secretary Yvette Cooper called Enhertu life-changing and said the yes followed changes the government made to the NICE framework as part of its US pharmaceuticals deal.

NICE posted the decision the same morning.

NICE recommends Enhertu for people with HER2-low advanced breast cancer.

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.

Learn more: https://t.co/hMe78NkWbS

— NICE (@NICEComms) September 17, 2026

The Yes Came After the QALY Threshold Moved

NICE said the commercial solution followed changes made to its methods as part of the UK/US Pharmaceutical Pricing Agreement. Those changes were an increase in cost-effectiveness thresholds that took effect on 2 April 2026, and a new method for assessing quality of life published on 27 August 2026.

The arrangement, announced on 1 December 2025 and published on 2 April 2026, commits the United Kingdom to raise the NICE QALY threshold from between £20,000 and £30,000 to between £25,000 and £35,000. It also tells the NHS to raise the net price paid for prospective new medicines by 25% from April 2026, and to adopt the EuroQol 5-level measure of health-related quality of life.

A QALY is one year of full health. NICE uses that unit to judge whether a drug’s extra time and extra comfort are worth the extra bill. Lift the cap, and a medicine that sat just above the old line can pass without the company matching the 2024 discount NHS England wanted.

WHAT THE DEAL CHANGED FOR NEW MEDICINES

The same text sets stepping stones of at least 0.35% of GDP on new medicines by the end of 2028 and 0.40% by the end of 2030. In return, the United States agreed not to put extra tariffs on UK pharmaceutical and medical-technology exports through 19 January 2029, if major UK firms keep to separate US pricing terms.

The 2024 clinical file did not grow a new survival curve. The bar that file had to clear did.

What DESTINY-Breast04 Measured in Extra Months

The case for Enhertu still rests on DESTINY-Breast04, the phase 3 study published in the New England Journal of Medicine in June 2022. Shanu Modi and colleagues randomised 557 adults with previously treated HER2-low advanced breast cancer. HER2-low means tumour cells carry a little of the HER2 protein (IHC 1+, or IHC 2+ with a negative in situ hybridisation test), a group that used to be treated as HER2-negative.

Among all patients, median time before the cancer worsened was 9.9 months on Enhertu and 5.1 months on the physician’s choice of chemotherapy, a gap of 4.8 months, with a hazard ratio of 0.50. Median overall survival was 23.4 months versus 16.8 months, a gap of 6.6 months, with a hazard ratio for death of 0.64 (P=0.001). The trial’s median overall survival of 23.4 months is the figure NICE’s yes still leans on.

DESTINY-BREAST04, ALL PATIENTS

Enhertu is an antibody-drug conjugate: trastuzumab homes in on HER2, and deruxtecan is the chemotherapy payload released at the cell. For HER2-low metastatic disease it is the first licensed targeted option. It is not a cure. Treatment aims to slow the cancer, add months, and hold quality of life as long as it can.

Nicolò Battisti, a consultant medical oncologist at the Royal Marsden, said the next job is prompt and fair rollout, “supported by accurate HER2 testing, so that every eligible patient can benefit without delay.” Labs that still report HER2 only as positive or negative will miss the people this decision was written for.

England Spent Two Years Stuck on Price

NICE’s independent committee could not recommend Enhertu at the price the companies first put forward. Talks were paused from December 2023. In 2024 the watchdog published a no, after saying Daiichi Sankyo and AstraZeneca had not offered a new price that counted as value for money, even after a severity modifier and after then Health Secretary Wes Streeting stepped in.

Breast Cancer Now, METUPUK and Make 2nds Count kept the fight public. Claire Rowney, chief executive of Breast Cancer Now, said in May 2026 that some of the women who campaigned in 2024 had since died without the drug. The charity’s thousands of people have missed out warning sat on a petition that asked the firms, NHS England and NICE to use the new April threshold and finish a deal.

THE PATH FROM TRIAL TO NHS LIST

1. June 2022: DESTINY-Breast04 reports longer survival than chemotherapy in HER2-low disease.
2. 2023: NHS Scotland starts offering Enhertu.
3. December 2023: NICE pauses its appraisal while price talks run.
4. 2024: NICE does not recommend the drug for England at the price then on the table.
5. 1 December 2025: London and Washington announce the pharmaceuticals arrangement.
6. 2 April 2026: The new QALY range takes effect.
7. 27 August 2026: NICE publishes the new quality-of-life method.
8. 17 September 2026: NICE recommends Enhertu; NHS England starts access.
9. 7 October 2026: Appeal window on the final draft closes at 5pm.

NICE still will not publish the confidential discount. Knight’s wording keeps both parts in view: a commercial solution, and the new thresholds. The public record does not show a fresh survival analysis. It shows a higher bar, a new quality-of-life tool, and a deal the companies would sign.

Scotland Has Offered the Same Drug Since 2023

Patients in Scotland have had NHS access since 2023. Breast Cancer Now said the medicine was also in use in 26 other European countries while England, Wales and Northern Ireland waited. That split, the same licence and the same trial, is what made the English no feel like a postcode rule rather than a clinical one.

WHERE PATIENTS CAN GET ENHERTU ON THE NHS

• Scotland: NHS use since 2023, years before NICE’s English yes.
• England: Prescribing from 17 September 2026 for about 1,000 people a year.
• Wales: Usually follows NICE; no separate start date in the English notice.
• Northern Ireland: Often mirrors NICE after a local endorsement step.

Rowney called 17 September 2026 a momentous day and then refused a clean celebration. “Today we can finally say we did it,” she said, adding that campaigners cannot mark the decision without remembering the cost of the delay. Ashley Dalton, Labour MP for West Lancashire, who lives with metastatic breast cancer, said the wait “has come at great cost” and that “we remember those who may still be here had they had access to Enhertu.”

Cooper thanked the charities. The political credit line is real. So is the mechanism: Scotland did not need a US trade text to list the drug in 2023. England listed it after that text moved NICE’s numbers.

MPs Ask the Audit Office to Cost the Deal

Enhertu is one product. The arrangement is a ten-year spend path. The House of Commons Library, in a briefing for an Estimates Day debate, said ministers put the extra cost at around £1 billion this Spending Review and will fund it from existing NHS budgets, with later years left to the 2027 review. The same briefing recorded Institute for Fiscal Studies figures of about £1.5 billion by 2028 and £9.1 billion in 2036. The government has said it has no plans to publish an impact assessment, calling the detail commercially sensitive.

On 15 September 2026, two days before the Enhertu notice, chairs of six Commons committees wrote to the National Audit Office asking for a rapid inquiry into the arrangement’s costs and value for money. Campaign groups Just Treatment and Global Justice Now have already asked ministers to revoke the regulations that let the government set NICE’s thresholds, arguing the move hits the institute’s independence.

WHERE EXPERTS DISAGREE

• Ministers: The deal protects UK drug exports, lifts access, and costs about £1 billion in this Spending Review, paid from current NHS budgets.
• Institute for Fiscal Studies: Extra costs run higher, about £1.5 billion by 2028 and £9.1 billion in 2036, as new-medicine spend scales toward 0.6% of GDP.
• NICE’s own caution: Knight said the institute must still protect other patient services when it pays more for new drugs.

Patient groups wanted the threshold rise. Industry wanted lower rebates and faster listings. The United States wanted Britain to pay more for new medicines. Each of those aims is now in force. Enhertu is the first cancer file large enough for the public to see the new arithmetic on a named ward.

Eligible patients in England can start treatment while the 7 October 2026 appeal window is still open. The NAO request sits on the same desk as the first English prescriptions.

Frequently Asked Questions

What Does HER2-Low Mean on a Pathology Report?

HER2-low means the tumour stains IHC 1+, or IHC 2+ with a negative in situ hybridisation test, so there is some HER2 protein but not the high level that older HER2 drugs were built for. DESTINY-Breast04 used that cut. Of 557 people in the trial, 494 (88.7%) had hormone-receptor positive disease and 63 (11.3%) had hormone-receptor negative disease.

How Does Trastuzumab Deruxtecan Differ From Ordinary Chemotherapy?

It is an antibody-drug conjugate. The trastuzumab antibody binds HER2 on the cancer cell and the deruxtecan payload is the chemotherapy released there, which is why a “low” HER2 score can still be a target. Standard chemotherapy in DESTINY-Breast04 was the physician’s choice after earlier treatment, not a HER2-directed drug.

What Is a QALY in a NICE Decision?

A quality-adjusted life year counts extra time and extra comfort as one unit, a year of full health. NICE’s standard range for that unit was £20,000 to £30,000 and is now £25,000 to £35,000. The UK-US text also orders a 25% rise in the net price of prospective new medicines from April 2026 and adoption of the EuroQol 5-level value set, so the same clinical benefit can look better on paper.

Can This NICE Decision Still Be Stopped?

The 17 September 2026 notice is final draft guidance, open to appeal until 5pm on 7 October 2026, a 20-day window. NHS England has already started access, so a successful appeal would have to unwind treatment that has begun. NICE said the review route exists when a new commercial arrangement appears, which is the route this file used.

Disclaimer: This article is news reporting on a NICE recommendation and an NHS access decision, and it is for information only. It is not medical advice, a treatment recommendation, or a substitute for a consultation with the oncologist, GP or specialist nurse responsible for an individual patient’s care. Anyone who thinks they may be eligible for trastuzumab deruxtecan should ask their own clinical team about HER2 testing, prior treatment and side effects, and should not start, stop or change medicine on the basis of this piece. Figures, eligibility and funding status reflect the NICE notice of 17 September 2026 and the government sources cited, and they may change if the guidance is appealed or if later commissioning rules differ.